New Study Shows Icosapent Ethyl Cuts Cardiovascular Risks Even for Aspirin Users
Amarin Corporation plc has revealed new findings from a post-hoc analysis of the REDUCE-IT® trial, reinforcing the cardiovascular benefits of icosapent ethyl in high-risk patients, including those taking aspirin. The study, conducted by Amarin, showed significant reductions in major adverse cardiovascular events in both aspirin users and non-users.
The REDUCE-IT study, led by Amarin, demonstrated that icosapent ethyl, marketed as VASCEPA®/VAZKEPA®, significantly reduced primary endpoint events in aspirin users by 28%, with an absolute risk reduction of 5.9% and a number needed to treat of 17. This benefit was consistent with the overall study population's safety profile.
The U.S. Food and Drug Administration (FDA) recently updated the labeling for fenofibrate products, stating that fibrates do not reduce cardiovascular risk when used in combination with statins. However, the REDUCE-IT trial's findings suggest that icosapent ethyl may offer additional cardiovascular protection for high-risk patients already on statin therapy, even if they are also taking aspirin.
Steven Ketchum, Ph.D., EVP, President of R&D, and Chief Scientific Officer at Amarin, highlighted the need for more effective, evidence-based approaches to residual cardiovascular risk. Deepak L. Bhatt, MD, MPH, MBA, Director of the Mount Sinai Fuster Heart Hospital in New York, supported the role of icosapent ethyl as a valuable option in comprehensive cardiovascular risk management.
Amarin Corporation's post-hoc analysis of the REDUCE-IT trial reinforces the cardiovascular benefits of icosapent ethyl in high-risk patients, including those taking aspirin. The findings suggest that icosapent ethyl may offer additional protection for high-risk patients already on statin therapy, even when used in combination with aspirin. Amarin remains committed to advancing the science of cardiovascular care and addressing residual risk in patients worldwide.
